Zakayo Mwangi

Zakayo Mwangi

Auto-generated profile, based on publicly available information

Zakayo Mwangi

Medical Laboratory Sciences, Meru University of Science and Technology, Meru

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
ZMZakayo Maingi
Zakayo Maingi
ANAnthony Kebira Nyamache
Anthony Kebira Nyamache
The fetal consequences of CMV infection have made it one of the most serious infections contracted during pregnancy. Despite the posed teratogenic risk during pregnancy, there is no national screening test for CMV infection is available during pregnancy in Kenya. Thus little is known on its epidemiological data that is necessary for health planners and care providers. A cross sectional study was conducted at Thika district level 5 hospital, Kenya to investigate seroprevalence of CMV infections and associated possible risk factors among pregnant women. Structured questionnaires were used to gather socio-demographic data and ELISA was used to detect CMV infections using IgG and IgM. Out of 260 pregnant women, 201 (77.3%) were CMV IgG 21(8.1%) CMV IgM being on acute stage of the disease. Marital status (OR = 3.7533, 95% CI =3.0231-6.9631, P < 0.0001), parity (OR = 3.7533, 95% CI = 3.0231-6.9631, P < 0.0001), and education (OR = 3.7533, 95% CI = 3.0231-6.9631, P < 0.0001), history of blood transfusion (OR = 0.0374, 95% CI = 0.00120-0.1168, OR = 0.3804) were found to significantly influence seropostivity in univariate analysis. The 88.4% CMV prevalence rate being detected among pregnant women calls for vaccine and routine screening for CMV infections and its associated risk factors in this kind of settings.

1 July 2024 in International Journal of Mycobacteriology
Verified
Journal Article
Open access
ZMZakayo Maingi Mwangi
Zakayo Maingi Mwangi
SISamson Ireri
Samson Ireri
HOHaron Opwaka
Haron Opwaka
LOLeon Otieno
Leon Otieno
JSJoan Simam
Joan Simam
NMNellie Mukiri
Nellie Mukiri
Background: Drug-resistant tuberculosis (DR-TB) poses a major global challenge to public health and therapeutics. It is an emerging global concern associated with increased morbidity and mortality mostly seen in the low- and middle-income countries. Molecular techniques are highly sensitive and offer timely and accurate results for TB drug resistance testing, thereby positively influencing patient management plan. Methods: The study was carried out at the National Tuberculosis Reference Laboratory (NTRL) in Kenya in the period between January and October 2022. A total of 243 Mycobacterium tuberculosis (M.tb) clinical isolates were included in the study. These isolates comprised of 50 isolates with mutations in rpoB, 51 isolates with katG mutations, 51 isolates with mutations in inhA, and 91 M.tb isolates lacking mutations in these genes based on Genotype MTBDRplus results. DNA from the isolates was extracted using the FluoroLyse extraction kit. Real-time polymerase chain reaction targeting the rpoB, InhA, and katG genes was performed using the FluoroType MTBDR amplification mix. Isolates with discordant results between Genotype MTBDRplus and FluoroCycler® MTBDR assays underwent targeted sequencing for the respective genes, then, sequences were analyzed for mutations using Geneious version 11.0 software. Results: The sensitivity of the Fluorocycler XT MTBDR assay for the detection of mutations that confer drug resistance was 86% (95% confidence interval [CI] 73.0–94.0) for rpoB, 96% (95% CI 87–100) for katG and 92% (95% CI 81–98) for inhA. The assay’s specificity was 97% (95% CI 93–99) for rpoB, 98% (95% CI 96–100) for katG, and 97% (95% CI 93–99) for inhA. Conclusion: The diagnostic accuracy of FluoroType MTBDR for the detection of mutations conferring resistance to rifampicin and isoniazid was high compared with that of Genotype MTBDRplus and demonstrates its suitability as a replacement assay for Genotype MTBDRplus.

5 December 2022 in F1000Research
Verified
Journal Article
Open access
PDF file
ZMZakayo Mwangi
Zakayo Mwangi
GNGrace Naeku
Grace Naeku
MMMarianne Mureithi
Marianne Mureithi
FOFrank Onyambu
Frank Onyambu
WBWallace Bulimo
Wallace Bulimo
Background: Nontuberculous mycobacteria (NTM) treatment constitutes a macrolide-based antibiotic regimen in combination with aminoglycosides for Rapid-Growing mycobacteria (RGM), and rifampicin for Slow-Growing mycobacteria (SGM). Mutations in the anti-NTM drug target regions promote NTM evolution to mutant strains that are insusceptible to NTM drugs leading to treatment failure. We, therefore, described the mutation patterns of anti-NTM drug target genes including rrl, rrs, and rpoB in NTM isolates from Kenya. Methods: We carried out a cross-sectional study that included 122 NTM obtained from the sputum of symptomatic tuberculosis-negative patients in Kenya. All the 122 NTM underwent targeted sequencing of the rrl gene. The 54 RGM were also sequenced for rrs, and the 68 SGM were sequenced for rpoB genes using ABI 3730XL analyzer. The obtained sequences were aligned to their wild-type reference sequences for each gene using Geneious then mutations were identified. Pearson chi-square at 95% confidence interval tested the association of NTM to mutation patterns for each gene. Results: Twenty-eight (23%) of the NTM harbored mutations associated with resistance to at least one of the macrolide-based therapy antibiotics. Twelve (10.4%) NTM comprising 7(58.3%) of RGM and 5(41.7%) of SGM had mutations in the rrl gene. For ten (83.3%) NTM, mutations were found at position 2058, while for two (16.6%) NTM, mutations were found at position 2059. Six (11.1%) of the 54 RGM exhibited mutations in the aminoglycoside target gene rrs at location 1408. Ten (14.7%) of the 68 SGM harbored mutations in the rpoB gene with 40 percent having mutations at codon 531. Conclusion: We demonstrated a significant level of mutations associated with drug resistance for macrolides, aminoglycosides, and rifampicin in NTM isolated from symptomatic TB negative patients in Kenya.

29 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ZMZakayo M Mwangi
Zakayo M Mwangi
NMNellie Mukiri
Nellie Mukiri
FOFrank G Onyambu
Frank G Onyambu
WBWallace Bulimo
Wallace Bulimo
Non-Tuberculous Mycobacteria (NTM) transmission to humans occurs through inhalation of dust particles or vaporized water containing NTM leading to pulmonary manifestations. NTM infections are often misdiagnosed for tuberculosis (TB) due to their similar clinical and radiological manifestations. We, therefore, performed a species-level identification of NTM in symptomatic TB negative patients through sequencing of the hsp65 gene. We conducted a cross-sectional study at the National Tuberculosis Reference Laboratory in the period between January to November 2020. One hundred and sixty-six mycobacterial culture-positive samples that tested negative for TB using capilia underwent Polymerase Chain Reaction targeting the hsp65 gene. Isolates showing a band with gel electrophoresis at 441 bp position were sequenced using Sanger technology. Geneious software was used to analyze the obtained sequences, and the National Center for Biotechnology Information gene database identified NTM species for each isolate. A phylogenetic tree was constructed from the DNA sequences and evolutionary distances computed using the general time-reversible method. Pearson chi-square was used to determine the association between NTM infection and participants’ characteristics Our study identified 43 different NTM species. The dominant NTM belonged to Mycobacterium avium complex 37 (31%). Slow-growing NTM were the majority at 86 (71%) while rapid-growing NTM were 36 (29%). A significant association (p<0.05) was observed for regions and age, while patient type had a week likelihood of NTM infection. Our study characterized the diversity of NTM in Kenya for the first time and showed a high diversity of NTM species.

9 July 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
GKGeorge Kamau
George Kamau
ZMZakayo Mwangi
Zakayo Mwangi
JBJoel Bargul
Joel Bargul
MOMaurice Owiny
Maurice Owiny
NMNellie Mukiri
Nellie Mukiri
RLRaphael Lihana
Raphael Lihana
Background: Mycobacterial pathogens are among the top causes of diseases in humans. In Kenya, incidences of Non-Tuberculous Mycobacteria (NTM) species have steadily been on the increase. Most NTMare resistant to first line treatment of tuberculosis and have a challenge in timely and accurate diagnosis. Misdiagnosis has led to prescribing anti-tuberculosis regimens to patients suffering from NTM. We aimed to determine the most prevalent Non-Tuberculous Mycobacterium in Kenya. Methods: We reviewed records from the National Tuberculosis Reference Laboratory(NTRL ) Laboratory information management system (LIMS) between January 2018 and December 2019 for the patients on surveillance. All isolates were cultured in Mycobacterial Growth Indicator Tubes (MGIT) and incubated for detection using BACTEC™ MGIT™ system. Those with negative acid-fast bacilli (AFB) growth and negative for Mycobacterium Tuberculosis Complex Species (MTBC) protein-MPT64 were suggestive of NTM infections, which were sub-cultured in MGIT and characterized using Line Probe Assay (LPA) GenoType® MTBDR CM/AS. Descriptive and bivariate analysis was done. Results: Of the total 24,549 records reviewed, 167(0.7%) were NTM isolates. Males comprised of 74.2% (124/167), and the mean age was 42 years (SD±16), age group 35-44 years had the highest NTM at 26.3% (44/167). Nairobi had 12.6% (21/167), Mombasa 10.8% (18/167), Kilifi and Meru each had 7.8% (13/167). Eleven isolated species comprised of Mycobacterium intracellulare 35.3% (65/167), M. fortuitum at 27% (48/167), and M. scrofulaceum at 10.2% (17/167). Previously treated patients had higher NTM [63.5% (106/167)] than Drug-resistant follow-up patients [26.9% (45/167)]. Coinfection with HIV was at 27.5% (46/167). Conclusion: Previously treated patients should have an additional screening of NTMS, and drug susceptibility testing should be done before initiation of treatment.

17 May 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ZMZakayo Maingi Mwangi
Zakayo Maingi Mwangi
SISamson Ireri
Samson Ireri
HOHaron Opwaka
Haron Opwaka
LOLeon Otieno
Leon Otieno
JSJoan Simam
Joan Simam
NMNellie Mukiri
Nellie Mukiri
Background: Drug-resistant TB (DR-TB) poses a major global challenge to public health and therapeutics. It is an emerging global concern associated with increased morbidity and mortality mostly seen in the low- and middle-income countries. Lack of adequate diagnostic equipment for detection and monitoring of DR-TB leads to delayed diagnosis and subsequent inappropriate treatment. TB drug resistance testing has relied on phenotypic presentations in drug sensitivity testing (DST). The cost of setting up a TB phenotypic testing facility is prohibitive for most healthcare facilities due to its intensive investment in infrastructure, equipment, laboratory consumables, and personnel. Molecular techniques are highly sensitive and offer timely and accurate results for TB drug resistance testing, thereby positively influencing patient management plan. The commonly used assay for detection of rifampicin (RIF) and isoniazid (INH) resistance in Mycobacterium tuberculosis (M.tb) is GenoType MTBDR plus . Although the GenoType MTBDR plus is more inexpensive and accurate than DST, when compared to other molecular techniques, it requires more specialized expertise, more hands-on time, substantial laboratory infrastructure and result interpretation is subjective to user. The FluoroCycler® MTBDR is a real-time polymerase chain reaction assay that detects M.tb and at the same time identifies mutations in rpoB, katG and inhA genes that are associated with RIF and INH resistance. It can detect up to 45 mutations in these genes in a single tube, producing results within 2.5 hours and this ability is only comparable to sequencing. Methods: The study was carried out at the National Tuberculosis Reference Laboratory (NTRL) in Kenya in the period between January to October 2022. A total of 243 M.tb clinical isolates were included in the study. These isolates comprised of 50 isolates with mutations in rpoB , 51 isolates with katG mutations, 51 isolates with mutations in inhA . and 91 M.tb isolates lacking mutations in these genes based on Genotype MTBDR plu s results. DNA from the isolates was extracted using the FluoroLyse extraction kit. Real-time PCR targeting the rpoB, InhA , and katG genes was performed using the FluoroType MTBDR amplification mix. Isolates with discordant results between Genotype MTBDR plu s and FluoroCycler® MTBDR assays underwent targeted sequencing for the respective genes, then sequences were analyzed for mutations using Geneious version 11.0 software. Results: The sensitivity of the Fluorocycler XT MTBDR assay for detection of mutations that confer drug resistance was 86% (95% CI 73.0,94.0) for rpoB , 96% (95% CI 87, 100) for katG and 92% (95% CI 81, 98) for inhA . The assay’s specificity was 97% (95% CI 93, 99) for rpoB , 98% (95% CI 96, 100) for katG and 97% (95% CI 93, 99) for inhA . Discrepancy between Genotype MTBDR plus and FluoroType MTBDR results were observed in 28 (11.5%) isolates with rpoB, katG and inhA genes having 26% (13/50), 10% (5/50), and 20% (10/50) isolates with discrepant results respectively. Sequencing results that were in agreement with FluoroType MTBDR results were 77% (10/13) for rpoB , 80% (4/5) for katG , and 70% (7/10) for inhA compared to 23% (3/13), 20% (1/5), and 30% (3/10) for Genotype MTBDR plus assay Conclusion: The diagnostic accuracy of FluoroType MTBDR for the detection of mutations conferring resistance to RIF and INH was high compared with that of Genotype MTBDR plus , and demonstrates its suitability as a replacement assay for Genotype MTBDR plus .